These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. Christiansen C; Chesnut CH; Adachi JD; Brown JP; Fernandes CE; Kung AW; Palacios S; Levine AB; Chines AA; Constantine GD BMC Musculoskelet Disord; 2010 Jun; 11():130. PubMed ID: 20569451 [TBL] [Abstract][Full Text] [Related]
26. Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA. Pinkerton JV; Bushmakin AG; Bobula J; Lavenberg J; Komm BS; Abraham L Menopause; 2017 Dec; 24(12):1372-1377. PubMed ID: 28609389 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787 [TBL] [Abstract][Full Text] [Related]
28. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Pickar JH; Komm BS Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836 [TBL] [Abstract][Full Text] [Related]
29. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ Menopause; 1999; 6(3):188-95. PubMed ID: 10486787 [TBL] [Abstract][Full Text] [Related]
30. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Lewiecki EM Expert Opin Investig Drugs; 2007 Oct; 16(10):1663-72. PubMed ID: 17922629 [TBL] [Abstract][Full Text] [Related]
31. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. Fleischer AC; Wheeler JE; Yeh IT; Kravitz B; Jensen C; MacDonald B J Ultrasound Med; 1999 Jul; 18(7):503-12. PubMed ID: 10400054 [TBL] [Abstract][Full Text] [Related]
33. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Genant HK Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498 [TBL] [Abstract][Full Text] [Related]
34. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Goldstein SR; Scheele WH; Rajagopalan SK; Wilkie JL; Walsh BW; Parsons AK Obstet Gynecol; 2000 Jan; 95(1):95-103. PubMed ID: 10636510 [TBL] [Abstract][Full Text] [Related]
35. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Harvey JA; Holm MK; Ranganath R; Guse PA; Trott EA; Helzner E Menopause; 2009; 16(6):1193-6. PubMed ID: 19503006 [TBL] [Abstract][Full Text] [Related]
36. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review. Taylor HS; Ohleth K Menopause; 2012 Apr; 19(4):479-85. PubMed ID: 22278343 [TBL] [Abstract][Full Text] [Related]
37. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial. Skouby SO; Pan K; Thompson JR; Komm BS; Mirkin S Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570 [TBL] [Abstract][Full Text] [Related]
38. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis. Kung AW; Chu EY; Xu L Expert Opin Pharmacother; 2009 Jun; 10(8):1377-85. PubMed ID: 19445558 [TBL] [Abstract][Full Text] [Related]
39. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382 [TBL] [Abstract][Full Text] [Related]